Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Platinum-DNA adduct formation refers to the covalent binding of platinum-based anticancer drugs (such as cisplatin, carboplatin, and oxaliplatin) to DNA. This process is central to the cytotoxic mechanism of these drugs, which are widely used in chemotherapy for various solid tumors. The platinum atom forms coordinate covalent bonds with nucleophilic sites on DNA bases—primarily the N7 position of guanine—resulting in a range of DNA lesions that disrupt cellular processes and trigger cell death.
Covalent binding to DNA, forming adducts that disrupt replication and transcription.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Platinum-DNA Adduct Formation.